Version 1
: Received: 5 November 2024 / Approved: 5 November 2024 / Online: 6 November 2024 (09:39:52 CET)
How to cite:
Rivas, S.; Sepulveda, R. V.; Tapia, I.; Estay, C.; Soto, V.; Blanco, A.; Gonzáles, E.; Armisen, R. MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American NSCLC patients.. Preprints2024, 2024110367. https://doi.org/10.20944/preprints202411.0367.v1
Rivas, S.; Sepulveda, R. V.; Tapia, I.; Estay, C.; Soto, V.; Blanco, A.; Gonzáles, E.; Armisen, R. MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American NSCLC patients.. Preprints 2024, 2024110367. https://doi.org/10.20944/preprints202411.0367.v1
Rivas, S.; Sepulveda, R. V.; Tapia, I.; Estay, C.; Soto, V.; Blanco, A.; Gonzáles, E.; Armisen, R. MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American NSCLC patients.. Preprints2024, 2024110367. https://doi.org/10.20944/preprints202411.0367.v1
APA Style
Rivas, S., Sepulveda, R. V., Tapia, I., Estay, C., Soto, V., Blanco, A., Gonzáles, E., & Armisen, R. (2024). MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American NSCLC patients.. Preprints. https://doi.org/10.20944/preprints202411.0367.v1
Chicago/Turabian Style
Rivas, S., Evelin Gonzáles and Ricardo Armisen. 2024 "MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American NSCLC patients." Preprints. https://doi.org/10.20944/preprints202411.0367.v1
Abstract
Targeted therapy indications for actionable variants in non-small cell lung cancer (NSCLC) have primarily been studied in Caucasian populations, with limited data on Latin American patients. This study utilized a 52-gene next-generation sequencing (NGS) panel to analyze 1,560 tumor biopsies from NSCLC patients in Chile, Brazil, and Peru. RNA sequencing reads, and DNA coverage were correlated to improve the detection of the actionable MET exon 14 skipping variant (METex14). The pathogenicity of MET variants of uncertain significance (VUS) was assessed using bioinformatic methods based on their predicted driver potential. The effects of the predicted driver VUS T992I and H1094Y on MET signaling activation, proliferation, and migration were evaluated in HEK293T, BEAS-2B, and H1993 cell lines. Subsequently, MET inhibitors were tested in 2D and 3D cell cultures, and drug affinity was determined using 3D structure simulations. The prevalence of MET variants in the South American cohort was 8%, and RNA-based diagnosis detected 27% more cases of METex14 than DNA-based methods. Notably, 20% of METex14 cases with RNA reads below the detection threshold were confirmed by DNA analysis. The novel actionable T992I and H1094Y variants induced proliferation and migration through c-Met/Akt signaling. Both variants showed sensitivity to crizotinib and savolitinib, but the H1094Y variant exhibited reduced sensitivity to capmatinib. These findings highlight the importance of RNA-based METex14 diagnosis and reveal the drug sensitivity profiles of novel actionable MET variants from an understudied patient population.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
